glucose, (beta-d)-isomer has been researched along with Dyslipidemias in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 6 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dvorakova, I; Haluzik, M; Huttl, M; Kasperova, BJ; Kratochvilova, H; Kuzma, M; Malinska, H; Markova, I; Melcova, M; Mraz, M; Oliyarnyk, O; Pelantova, H; Rosolova, K; Skop, V; Stemberkova-Hubackova, S; Svoboda, P; Trnovska, J | 1 |
| Al-Wakeel, DE; El-Kashef, DH; Nader, MA | 1 |
| Hashimoto, N; Kawai, H; Ohara, T; Onishi, T; Sawada, T; Shimane, A; Takaya, T; Taniguchi, Y; Uzu, K; Yasaka, Y | 1 |
| Masuda, D; Yamashita, S | 1 |
| Cirule, H; Dambrova, M; Korzh, S; Kuka, J; Liepinsh, E; Makrecka-Kuka, M; Videja, M; Vilks, K | 1 |
| Chen, YY; Jiang, MM; Liang, QQ; Lu, JX; Shi, H; Wen, SY; Wu, Q; Yao, ZH; Zhu, Y | 1 |
| He, S; Meng, X; Sun, G; Sun, X; Wang, R; Ye, T; Zhang, C | 1 |
| Gupta, Y; Kalra, S; Kishor, K | 1 |
| Briand, F; Brousseau, E; Burr, N; Costard, C; Mark, M; Mayoux, E; Sulpice, T; Urbain, I | 1 |
| Cao, L; Hao, Y; Ling, W; Liu, J; Ma, J; Mou, H; Qin, Y; Xia, M | 1 |
1 review(s) available for glucose, (beta-d)-isomer and Dyslipidemias
| Article | Year |
|---|---|
The cardiovascular phenotype: impact on choice of glucose- lowering therapy.
Topics: Acarbose; Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Glucosides; Heart Rate; Humans; Hypoglycemic Agents; Metformin; Obesity; Phenotype | 2016 |
1 trial(s) available for glucose, (beta-d)-isomer and Dyslipidemias
| Article | Year |
|---|---|
Anthocyanin supplementation improves serum LDL- and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer protein in dyslipidemic subjects.
Topics: Adult; Aged; Anthocyanins; Biological Transport; Cell Line; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Dyslipidemias; Female; Fruit; Glucosides; Humans; Male; Middle Aged; Phytotherapy; Plant Extracts | 2009 |
8 other study(ies) available for glucose, (beta-d)-isomer and Dyslipidemias
| Article | Year |
|---|---|
Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress.
Topics: 3T3-L1 Cells; Adipose Tissue; Administration, Oral; Animals; Benzhydryl Compounds; Cell Survival; Cellular Senescence; Disease Models, Animal; Down-Regulation; Dyslipidemias; Gluconeogenesis; Glucosides; Hep G2 Cells; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistance; Kidney; Lipogenesis; Liver; Male; Mice; Oxidative Stress; Rats; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Up-Regulation; Weight Gain | 2021 |
Renoprotective effect of empagliflozin in cafeteria diet-induced insulin resistance in rats: Modulation of HMGB-1/TLR-4/NF-κB axis.
Topics: Animals; Benzhydryl Compounds; Diet; Dyslipidemias; Glucosides; HMGB Proteins; Insulin; Insulin Resistance; NF-kappa B; Rats; Toll-Like Receptor 4 | 2022 |
Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease.
Topics: Benzhydryl Compounds; Body Weight; Cardiometabolic Risk Factors; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Endothelium, Vascular; Female; Glucose; Glucosides; Hemodynamics; Humans; Lipid Metabolism; Male; Middle Aged; Outcome Assessment, Health Care; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2020 |
Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin.
Topics: Benzhydryl Compounds; Cardiometabolic Risk Factors; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Endothelium, Vascular; Glucose; Glucosides; Humans; Lipid Metabolism; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2020 |
Empagliflozin Protects Cardiac Mitochondrial Fatty Acid Metabolism in a Mouse Model of Diet-Induced Lipid Overload.
Topics: Animals; Benzhydryl Compounds; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Energy Metabolism; Glucosides; Male; Mice, Inbred C57BL; Mitochondria, Heart; Oxidation-Reduction; Palmitates; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Modulation of hepatic lipidome by rhodioloside in high-fat diet fed apolipoprotein E knockout mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Chromatography, Liquid; Diet, High-Fat; Dyslipidemias; Glucosides; Lipid Metabolism; Lipids; Liver; Male; Mice, Inbred C57BL; Mice, Knockout; Mice, Knockout, ApoE; Phenols; Tandem Mass Spectrometry | 2020 |
Gastrodin Alleviates Cognitive Dysfunction and Depressive-Like Behaviors by Inhibiting ER Stress and NLRP3 Inflammasome Activation in db/db Mice.
Topics: Animals; Apoptosis; Behavior, Animal; Benzyl Alcohols; Blood Glucose; Body Weight; Cognitive Dysfunction; Depression; Dyslipidemias; Endoplasmic Reticulum Stress; Glucosides; Inflammasomes; Insulin Resistance; Male; Memory; Mice; Models, Biological; Neurons; Neuroprotective Agents; NLR Family, Pyrin Domain-Containing 3 Protein | 2018 |
Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cholesterol, LDL; Cricetinae; Diet, High-Fat; Dyslipidemias; Energy Metabolism; Glucosides; Hypoglycemic Agents; Intestinal Mucosa; Intestines; Lipid Metabolism; Male; Mesocricetus | 2016 |